Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.31 |
| ▸ | ITGAV | P06756 | 2/20 | 0.31 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4339792 | 0.78 | TAS2R14 (0.38) | — | |
| SCHEMBL4344331 | 0.67 | SMN1; SMN2 (0.42) | ALDH1A1 | |
| SCHEMBL4344286 | 0.67 | LMNA (0.44) | ALDH1A1 | |
| SCHEMBL17135589 | 0.61 | ESRRG (0.33) | ITGB3ITGB1ITGAVITGA5ALDH1A1 | |
| SCHEMBL6539645 | 0.60 | MAPT (0.38) | ALDH1A1 | |
| SCHEMBL6539634 | 0.60 | MAPT (0.38) | ALDH1A1 | |
| SCHEMBL19140552 | 0.59 | KLK7 (0.35) | ALDH1A1 | |
| SCHEMBL6541438 | 0.59 | CAPN1 (0.38) | ALDH1A1 | |
| SCHEMBL6541442 | 0.59 | CAPN1 (0.38) | ALDH1A1 | |
| SCHEMBL2959941 | 0.57 | BCHE (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | ITGB3 4528/4885ITGB1 4679/4885ITGAV 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.